Immutep Limited (PRRUF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Immutep Limited (PRRUF) trades at $0.0379 with AI Score 55/100 (Grade B). Immutep Limited (PRRUF) is an Australian biotechnology firm focused on developing immunotherapeutic pharmaceuticals targeting cancer and autoimmune diseases. Market cap: $55.9M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for PRRUF: PRRUF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PRRUF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PRRUF: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Immutep Limited (PRRUF) Healthcare & Pipeline Overview
Immutep Limited (PRRUF) is a biotechnology company specializing in innovative immunotherapeutics, particularly in the treatment of cancer and autoimmune diseases, with a strong focus on LAG-3 as a therapeutic target.
What Is the Investment Thesis for PRRUF?
Immutep Limited presents a compelling investment thesis driven by its innovative pipeline and strategic partnerships. The company's lead candidate, eftilagimod alpha, is in a Phase IIb trial, with results expected to significantly impact its valuation and market position. The growing interest in LAG-3 as a therapeutic target in immuno-oncology could enhance the company's competitive edge. Additionally, the collaboration with established pharmaceutical companies such as GlaxoSmithKline and Novartis provides financial backing and expertise, potentially accelerating product development timelines. However, investors should be cautious of the inherent risks associated with clinical trials and the OTC market's liquidity challenges. Monitoring upcoming trial results and potential uplisting efforts will be crucial for assessing the company's growth trajectory.
Based on FMP financials and quantitative analysis
PRRUF Key Highlights
Market Cap of $55.9M reflects the company's current valuation amid ongoing clinical trials.
- Profit Margin of -1404.1% indicates significant investment in research and development relative to revenue.
- Gross Margin of -522.6% highlights the early-stage nature of product development and commercialization.
- Beta of 2.24 suggests higher volatility compared to the broader market, characteristic of biotech stocks.
- No dividend yield as the company reinvests earnings into R&D for its innovative pipeline.
Who Are PRRUF's Competitors?
PRRUF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| JNJ Johnson & Johnson | $267.37 | -2.21% | $644B | 90 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PRRUF's Key Strengths?
Innovative pipeline targeting significant unmet medical needs in oncology and autoimmune diseases.
- Strong partnerships with major pharmaceutical companies enhance development capabilities.
- Expertise in LAG-3 as a therapeutic target positions the company favorably in the market.
What Are PRRUF's Weaknesses?
Negative profit margins indicate high R&D costs and early-stage commercialization challenges.
- Dependence on successful clinical trial outcomes for product advancement.
- OTC market listing may limit visibility and investor interest compared to major exchanges.
What Could Drive PRRUF Stock Higher?
PRRUF catalyst: Results from Phase IIb trial of eftilagimod alpha for metastatic breast cancer, expected in the near term.
- Progress in clinical trials for TACTI-002 and TACTI-003, targeting head and neck squamous cell carcinoma.
- Evaluation of INSIGHT-003 and INSIGHT-005 trials for solid tumors.
- Potential announcements regarding new partnerships or collaborations with pharmaceutical companies.
- Monitoring of market trends in immuno-oncology that may affect investor interest.
What Are the Key Risks for PRRUF?
Financial-distress signal — its Altman Z-Score of -5.18 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-69.2%) — the business is not currently generating profit on shareholder capital.
- Regulatory hurdles could delay clinical trial approvals and product launches.
- Market volatility and liquidity risks associated with trading on the OTC market.
- Competition from established biotech firms could impact market share.
- Dependence on successful clinical trial outcomes for future revenue generation.
What Are the Growth Opportunities for PRRUF?
- Immutep's lead candidate, eftilagimod alpha, targets this lucrative segment, providing a strong growth avenue as clinical trials progress and potential approvals are sought.
- Partnerships with Major Pharmaceutical Companies: Collaborations with industry leaders like GlaxoSmithKline and Novartis can enhance Immutep's R&D capabilities and market reach. These partnerships may facilitate accelerated development timelines and increased funding, positioning the company favorably within the competitive landscape.
- Development of Additional Pipeline Products: Immutep's portfolio includes several promising candidates, such as IMP761 and IMP701, targeting both cancer and autoimmune diseases. Successful advancement through clinical trials could diversify revenue streams and reduce reliance on a single product, enhancing overall company stability.
- Geographic Market Expansion: As Immutep continues to develop its products, entering new geographic markets, particularly in North America and Europe, could significantly increase its market share. The growing demand for innovative cancer therapies in these regions presents a valuable opportunity for expansion.
- Increased Interest in LAG-3 Targeting: The rising focus on LAG-3 as a therapeutic target in immuno-oncology could lead to increased investment and research opportunities. As clinical data supporting LAG-3's efficacy emerges, Immutep may benefit from heightened interest and collaboration within the biotech community.
What Are PRRUF's Competitive Advantages?
- Strong focus on LAG-3, a novel therapeutic target in immuno-oncology.
- Established partnerships with leading pharmaceutical companies enhance credibility and resources.
- Innovative pipeline with multiple candidates in various stages of clinical trials reduces dependency on a single product.
What Does PRRUF Do?
Founded in 1987, Immutep Limited, originally known as Prima BioMed Ltd, is an Australian biotechnology company headquartered in Sydney. The firm is dedicated to the discovery and development of cutting-edge immunotherapeutic pharmaceuticals aimed primarily at treating cancer and autoimmune diseases. Over the years, Immutep has evolved its focus towards LAG-3, a protein that plays a crucial role in regulating immune responses. Its flagship product, eftilagimod alpha (also referred to as efti or IMP321), is currently undergoing a Phase IIb clinical trial to assess its efficacy as a chemo-immunotherapy combination for metastatic breast cancer. In addition to efti, Immutep is advancing several other oncology candidates, including TACTI-002 and TACTI-003, both of which are in Phase II trials targeting head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer. The company is also exploring novel treatments for solid tumors through its INSIGHT-003 and INSIGHT-005 trials. Furthermore, Immutep's portfolio includes IMP761, aimed at autoimmune conditions, IMP701, which stimulates T cell proliferation in cancer, and IMP731, designed to deplete T cells associated with autoimmunity. Collaborating with major pharmaceutical partners such as GlaxoSmithKline, Novartis, and Merck, Immutep is well-positioned in the biotechnology landscape, leveraging its innovative pipeline to address significant unmet medical needs.
What Products and Services Does PRRUF Offer?
- Develop innovative immunotherapeutic pharmaceuticals targeting cancer and autoimmune diseases.
- Conduct clinical trials to evaluate the efficacy of their lead product, eftilagimod alpha.
- Collaborate with major pharmaceutical companies for research and development.
- Focus on LAG-3 as a therapeutic target in immuno-oncology.
- Maintain a diverse pipeline of candidates addressing various oncological and autoimmune conditions.
- Operate from headquarters in Sydney, Australia, with a global market focus.
How Does PRRUF Make Money?
- Generate revenue through partnerships and collaborations with larger pharmaceutical companies.
- Focus on clinical trial advancements to bring products to market.
- Leverage intellectual property and proprietary technologies to maintain competitive advantage.
What Industry Does PRRUF Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in immunotherapy and personalized medicine. With the global immunotherapy market projected to reach approximately $200 billion by 2026, companies like Immutep Limited are well-positioned to capitalize on this trend. The competitive landscape includes established players and emerging biotech firms, all vying for a share of the lucrative oncology market. Immutep's focus on LAG-3 as a therapeutic target differentiates it from competitors, aligning with the industry's shift towards innovative immune-based therapies.
Who Are PRRUF's Key Customers?
- Pharmaceutical companies seeking innovative therapeutic partnerships.
- Healthcare providers and institutions involved in cancer treatment.
- Patients requiring advanced immunotherapy options for cancer and autoimmune diseases.
Immutep Limited Financial Trajectory
Immutep Limited (PRRUF) reported $4.1M in revenue for Q4 2025, reflecting 330.2% growth compared to the prior quarter. The company recorded a net loss of $44.8M, with diluted EPS of $-0.03. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, PRRUF averaged $-0.02 in diluted EPS.
Company Profile
Immutep Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sydney, AU. The company is led by CEO Marc Voigt. PRRUF has traded publicly since 2012.
How Immutep Limited Is Valued
Immutep Limited carries a market capitalization of $55.9M, placing it in the micro-cap category. Relative to its peer group, PRRUF's quantitative score of 55/100 is below the peer average of 86/100.
Key Financial Metrics
Return on equity for Immutep Limited stands at -69.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -57.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -81.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -109.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Immutep Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.18 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Immutep Limited has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 10.0% above estimates on average.
Forward Outlook
Wall Street analysts project Immutep Limited revenue of about $16.3M for fiscal 2026, with EPS near $-0.02. The estimate reflects 5 contributing analysts.
PRRUF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Immutep's future prospects, indicating that those closest to the company believe in its potential growth.
- Community sentiment has shifted positively as discussions around Immutep's pipeline developments have gained traction, reflecting optimism among investors.
- The ongoing advancements in Immutep's clinical trials have captured attention, with many viewing the company's research as a potential game changer in immunotherapy.
- Market perception has been bolstered by strategic partnerships that could enhance Immutep's market position and accelerate product development.
Bear Case
- Despite recent positive sentiment, some analysts express concerns over the competitive landscape in the immunotherapy sector, which could impact Immutep's market share.
- Community discussions reveal skepticism regarding the timeline for product approvals, with some investors worried about potential delays in clinical trials.
- Insider selling activity, although not significant, has raised questions about the long-term outlook and commitment of certain executives, leading to bearish sentiment.
- The volatility in biotech stocks remains a concern, as market fluctuations can disproportionately affect companies like Immutep, which are still in the developmental phase.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $4M | -$45M | -$0.03 |
| Q2 2025 | $948,051 | -$20M | -$0.01 |
| Q4 2024 | $3M | -$22M | -$0.02 |
| Q2 2024 | $2M | -$21M | -$0.02 |
Based on FMP financials and quantitative analysis
PRRUF Latest News
No recent news available for PRRUF.
PRRUF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PRRUF.
Price Targets
Wall Street price target analysis for PRRUF.
PRRUF MoonshotScore
What does this score mean?
The MoonshotScore rates PRRUF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Marc Voigt
CEO
Marc Voigt has extensive experience in the biotechnology sector, having held various leadership roles in both public and private companies. He has a strong background in corporate strategy, business development, and operations, which he leverages to guide Immutep's strategic direction. Voigt holds a degree in economics and has been instrumental in advancing the company's innovative pipeline.
Track Record: Under Marc Voigt's leadership, Immutep has successfully transitioned into a focused biotechnology firm with a strong emphasis on LAG-3 therapies. His strategic partnerships with major pharmaceutical companies have enhanced the company's R&D capabilities and market positioning.
PRRUF OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. These stocks may have lower trading volumes and higher volatility, which can impact liquidity and investor access.
- OTC Tier: OTC Other
- Limited liquidity may affect the ability to buy or sell shares without impacting the stock price.
- Regulatory risks associated with clinical trials and product approvals can lead to volatility.
- Potential for increased scrutiny from investors due to the OTC listing status.
- Review clinical trial results and timelines for pipeline products.
- Monitor updates on partnerships and collaborations with pharmaceutical companies.
- Assess the company's financial health through available public disclosures.
- Evaluate the competitive landscape and market positioning of Immutep's products.
- Stay informed about regulatory developments affecting the biotechnology sector.
- Established partnerships with reputable pharmaceutical companies.
- Presence of experienced leadership with a strong track record in biotechnology.
- Active participation in clinical trials and research initiatives.
What Investors Ask About Immutep Limited (PRRUF) — Healthcare
What does the AI Score mean for PRRUF?
PRRUF holds an AI Score of 55/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Immutep Limited (PRRUF) is an Australian biotechnology firm focused on developing immunotherapeutic pharmaceuticals targeting cancer and autoimmune diseases. The company is known for its lead …
What does Immutep Limited do?
Immutep Limited is an Australian biotechnology company focused on developing innovative immunotherapeutic pharmaceuticals primarily targeting cancer and autoimmune diseases. The company’s lead product, eftilagimod alpha, is currently in clinical trials, exploring its efficacy in combination with chemotherapy for metastatic breast cancer, alongside a diverse pipeline of other candidates aimed at various oncological and autoimmune conditions.
What are the key growth opportunities for PRRUF in healthcare?
Immutep Limited has several key growth opportunities, including the expansion of its lead product, eftilagimod alpha, into new therapeutic areas and geographic markets. The increasing global demand for immunotherapy, particularly in oncology, positions the company favorably as it advances its clinical trials and explores new partnerships with pharmaceutical giants.
What are the main risks for PRRUF?
Immutep Limited faces several risks, including regulatory hurdles that could impact the approval timelines of its clinical trials and products. Additionally, being listed on the OTC market presents liquidity challenges and potential volatility, while competition from established biotech firms poses a threat to its market share and growth prospects.
What are the key factors to evaluate for PRRUF?
Immutep Limited (PRRUF) holds an AI score of 55/100 (moderate). Immutep Limited presents a compelling investment thesis driven by its innovative pipeline and strategic partnerships. Not financial advice.
How frequently does PRRUF data refresh on this page?
PRRUF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PRRUF's recent stock price performance?
Immutep Limited (PRRUF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline targeting significant unmet medical needs in oncology and autoimmune diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PRRUF overvalued or undervalued right now?
Immutep Limited (PRRUF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PRRUF before investing?
Before investing in Immutep Limited (PRRUF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of June 2026.